Check for updates

OPEN ACCESS

EDITED BY Xiangzhi Bai, Beihang University, China

REVIEWED BY

I-Shiang Tzeng, National Taipei University, Taiwan Zuhua Song, Chongqing General Hospital, China Zhiyuan Yu, Sichuan University, China

*CORRESPONDENCE

Hongsheng Lin tlinhsh@jnu.edu.cn Minghui Tan tanminghui@jnu.edu.cn

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience

RECEIVED 12 May 2022 ACCEPTED 15 July 2022 PUBLISHED 10 August 2022

CITATION

Zou J, Chen H, Liu C, Cai Z, Yang J, Zhang Y, Li S, Lin H and Tan M (2022) Development and validation of a nomogram to predict the 30-day mortality risk of patients with intracerebral hemorrhage. *Front. Neurosci.* 16:942100. doi: 10.3389/fnins.2022.942100

COPYRIGHT

© 2022 Zou, Chen, Liu, Cai, Yang, Zhang, Li, Lin and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Development and validation of a nomogram to predict the 30-day mortality risk of patients with intracerebral hemorrhage

Jianyu Zou^{1†}, Huihuang Chen^{2†}, Cuiqing Liu^{3†}, Zhenbin Cai¹, Jie Yang¹, Yunlong Zhang¹, Shaojin Li¹, Hongsheng Lin^{1*} and Minghui Tan^{1*}

¹Department of Orthopaedics, The First Affiliated Hospital of Jinan University, Guangzhou, China, ²Department of Rehabilitation, The First Affiliated Hospital of Jinan University, Guangzhou, China, ³Department of Nursing, The First Affiliated Hospital of Jinan University, Guangzhou, China

Background: Intracerebral hemorrhage (ICH) is a stroke syndrome with an unfavorable prognosis. Currently, there is no comprehensive clinical indicator for mortality prediction of ICH patients. The purpose of our study was to construct and evaluate a nomogram for predicting the 30-day mortality risk of ICH patients.

Methods: ICH patients were extracted from the MIMIC-III database according to the ICD-9 code and randomly divided into training and verification cohorts. The least absolute shrinkage and selection operator (LASSO) method and multivariate logistic regression were applied to determine independent risk factors. These risk factors were used to construct a nomogram model for predicting the 30-day mortality risk of ICH patients. The nomogram was verified by the area under the receiver operating characteristic curve (AUC), integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA).

Results: A total of 890 ICH patients were included in the study. Logistic regression analysis revealed that age (OR = 1.05, P < 0.001), Glasgow Coma Scale score (OR = 0.91, P < 0.001), creatinine (OR = 1.30, P < 0.001), white blood cell count (OR = 1.10, P < 0.001), temperature (OR = 1.73, P < 0.001), glucose (OR = 1.01, P < 0.001), urine output (OR = 1.00, P = 0.020), and bleeding volume (OR = 1.02, P < 0.001) were independent risk factors for 30-day mortality of ICH patients. The calibration curve indicated that the nomogram was well calibrated. When predicting the 30-day mortality risk, the nomogram exhibited good discrimination in the training and validation cohorts (C-index: 0.782 and 0.778, respectively). The AUCs were 0.778, 0.733, and 0.728 for the nomogram, Simplified Acute Physiology Score II (SAPSII), and Oxford Acute Severity of Illness Score (OASIS), respectively, in the validation cohort. The IDI and NRI calculations and DCA analysis revealed that the

nomogram model had a greater net benefit than the SAPSII and OASIS scoring systems.

Conclusion: This study identified independent risk factors for 30-day mortality of ICH patients and constructed a predictive nomogram model, which may help to improve the prognosis of ICH patients.

KEYWORDS

intracerebral hemorrhage, MIMIC III database, prognosis, nomogram, mortality

Background

Intracerebral hemorrhage (ICH) refers to primary, spontaneous, and non-traumatic hemorrhage that occurs in the brain parenchyma (Morotti and Goldstein, 2016; Watson et al., 2022). It is a common and the most severe hemorrhagic stroke syndrome, with a 30-day mortality rate higher than 40%, and most survivors are severely disabled (An et al., 2017). More than 2.8 million people worldwide reportedly die each year due to ICH (Schrag and Kirshner, 2020). ICH usually occurs in small arterioles affected by cerebral small vessel disease (SVD) (Hostettler et al., 2019). It is generally accepted that deep perforator arteriopathy (also termed hypertensive arteriopathy or arteriolosclerosis) (Hostettler et al., 2019; Schreiber et al., 2020) and cerebral amyloid angiopathy (CAA) (Banerjee et al., 2017; Weber et al., 2018) are the most common forms of sporadic SVD to induce ICH. In addition, certain gene mutations are related to the severity of ICH (Devan et al., 2013; Jones et al., 2019; Tang et al., 2021).

In contrast to the significant progress that has been made in the clinical treatment of ischemic stroke, the ideal management of ICH is undetermined (Kirshner and Schrag, 2021). It is currently believed that comprehensive supportive care in the acute phase after onset is the most effective treatment of ICH patients (Hemphill et al., 2015; Parry-Jones et al., 2020). Clinical trials in the United States showed that interventional surgery or drug therapy cannot effectively reduce the mortality or morbidity of ICH (Wilkinson et al., 2018). Therefore, the risk factors that affect prognosis after cerebral hemorrhage should be comprehensively studied, especially in intensive care units (ICUs).

Doctors and scholars have been committed to investigating the risk factors that lead to the unfavorable prognosis of ICH patients. Age (Forti et al., 2016), cancer (Gon et al., 2018), infection (Lord et al., 2014), and deep vein thrombosis (Cai et al., 2021) are risk factors for the unfavorable prognosis of ICH patients. A nomogram is a graphical tool used to determine the probability of an individual experiencing a clinical event based on a statistical prediction model (Zheng et al., 2016). Nomograms that predict risk factors for mortality of ICH patients have received little attention. The purpose of our research was to develop a nomogram that can predict the 30day mortality risk of ICH patients and thereby guide clinical practice.

Materials and methods

Data source

All data were extracted from the Medical Information Mart for Intensive Care III (MIMIC-III) database. MIMIC-III contains data associated with 53,423 distinct hospital admissions of adult patients (aged 16 years or older) admitted to critical care units at the Beth Israel Deaconess Medical Center in Boston, Massachusetts from 2001 to 2012 (Johnson et al., 2016). The information in the database is anonymous and therefore informed consent was not required for this study. The research personnel completed a series of courses provided by the National Institutes of Health and obtained authorization to access the MIMIC-III database after completing the required assessment (certificate number 40269495).

Patients and variables

The required data were extracted using the Structured Query Language in Navicat Premium (version 11.2.7.0). ICD-9 code 431 was used to extract patients diagnosed with ICH from the MIMIC-III database. The exclusion criteria were as follows: (1) first diagnosis not ICH, (2) younger than 18 years old, and (3)

Abbreviations: AKI, acute kidney injury; APSIII, Acute Physiology Score III; AUC, the area under the receiver operating characteristic curve; BP, blood pressure; BUN, blood urea nitrogen; CAA, cerebral amyloid angiopathy; CI, confidence interval; DCA, decision curve analysis; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; ICU, Intensive Care Unit; IDI, integrated discrimination improvement; INR, international normalized ratio; MIMIC-III, Medical Information Mart for Intensive Care III; NIH, National Institutes of Health; NRI, net reclassification improvement; OASIS, Oxford Acute Severity of Illness Score; OR, odds ratio; PT, prothrombin time; PTT, Partial thromboplastin time; ROC, receiver operating characteristic curve; SAH, subarachnoid hemorrhage; SAPSII, Simplified Acute Physiology Score II; SOFA, Sepsis-related Organ Failure Assessment; SpO₂, the saturation of peripheral oxygen; SQL, structured query language; SVD, small vessel disease; WBC, white blood cell.



less than 24 h of treatment in an ICU. The flow diagram of the study is shown in **Figure 1**.

The icustay_id parameter was used to extract data, including age, sex, marital status, ethnicity, severity score, comorbidities, vital signs, laboratory parameters, bleeding volume, and lesion location from the corresponding table. In terms of comorbidities, chronic pulmonary diseases, hypothyroidism, renal failure, liver disease, fluid electrolyte disorders, coagulopathy, obesity, heart diseases, diabetes, other neuronal dysfunctions, and anemias were mainly extracted. The vital sign values used, including heart rate, blood pressure, respiratory rate, temperature, saturation of peripheral oxygen, glucose, and urine output, were the average values measured over 24 h before ICU admission. The laboratory results were anion gap, bicarbonate, creatinine, chloride, glucose, hematocrit, hemoglobin, platelet, and potassium levels, partial thromboplastin time, international normalized ratio, prothrombin time, blood urea nitrogen level, and white blood cell (WBC) count. Severity scoring systems included the Angus implementation of the international consensus conference definition of severe sepsis, Simplified Acute Physiology Score II (SAPSII), Sequential Organ Failure Assessment, Oxford Acute Severity of Illness Score (OASIS), Acute Physiology Score III, and Glasgow Coma Scale (GCS) score. The raw data for this study are provided as **Supplementary Data 1**.

The event outcome was 30-day mortality of ICH patients hospitalized in an ICU. Patients who were alive at the time of discharge were designated as survivors.

Statistical analysis

Missing data are common in the MIMIC-III database and were explained using multiple imputations. All indicators with more than 20% missing values were eliminated. The "mice" package of R software was used to obtain ten estimated data sets. All ICH patients were randomly divided into training (70%) and validation (30%) cohorts. The former was used to build a nomogram and perform internal verification, while the latter was used to perform external verification. Categorical variables were expressed as frequency/percentage, and the chi-square test or Fisher's exact test was used to compare different groups. The Shapiro–Wilk test was used to determine whether a continuous variable had a normal distribution. If a continuous variable was normally distributed, it was described as the mean and standard deviation. If a continuous variable was not normally distributed, it was described as the median and interquartile range.

Logistic regression was applied to determine the independent risk factors for mortality of ICH patients within 30 days. First, risk factors were identified by performing least absolute shrinkage and selection operator (LASSO) regression analysis to resolve the collinear effect (OASIS and SAPSII scores were not included as variables in subsequent studies). LASSO analysis, a method to select variables among a large number of variables for predicting outcomes, reduces the coefficient of irrelevance while retaining important variables (Zhang and Hong, 2017). The code and data set of LASSO regression are provided as Supplementary Data 1, 2. Next, different AUC values within the range of lambda were estimated using a cross-validation technique. The maximum value of lambda when the cross-validation error was within one standard error of the minimum value was chosen. In accordance with previous studies, the probability threshold for entry was 0.05 and the threshold for removal was 0.10 in this step (Xu et al., 2021). The selected variables were then subjected to multivariate logistic regression analysis in order to identify independent prognostic factors, and the results were denoted as odds ratios (ORs) and 95% confidence intervals (CIs). Finally, a nomogram was constructed based on independent prognostic factors and used to predict the 30-day mortality of ICH patients.

Subsequently, multiple indicators were used to verify the nomogram internally and externally. The area under the receiver operating characteristic curve (AUC) was utilized to evaluate the predictive ability of the contour map of the nomogram, and the AUC value was compared with those of the SAPSII and OASIS scoring systems. The statistical significance of the improvement in AUC was calculated by Delong's test (DeLong et al., 1988). Receiver operating characteristic (ROC) curves were used to determine the optimal cut-off and its sensitivity and specificity according to the Youden index. In addition, integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were applied to calculate the difference between the constructed model and the SAPSII and OASIS scoring systems for predicting the 30-day mortality of ICH patients. In addition, a calibration curve was constructed and the calibration of the nomogram was evaluated using the Hosmer-Lemeshow test. Decision curve analysis (DCA) is a widely used tool in cancer research to determine the clinical value of predictive models. Therefore, to further measure the advantages of the constructed nomogram model, DCA was performed to compare the clinical applicability of the nomogram and that of the SAPSII and OASIS scoring systems. This was achieved by calculating the net benefits for a range of threshold probabilities.

R (version 4.0.3) and SPSS (version 24.0) software were used for statistical analyses. P < 0.05 was considered statistically significant.

Results

Baseline characteristics

After applying the inclusion and exclusion criteria, 890 ICH patients were identified from the MIMIC-III database (623 and 267 in the training and validation cohorts, respectively). Length of ICU stay (2.93 [1.78, 6.34] days versus 2.89 [1.88, 7.71] days, P = 0.303), length of admission (8.12 [4.28, 14.44] days versus 8.60 [4.60, 15.76] days, P = 0.51), and mortality rate (31.9% versus 37.1%, P = 0.158) did not significantly differ between the two groups. In the training and validation cohorts, females accounted for 46.9 and 41.2% of ICH patients, respectively. The median ages of patients in the training and validation cohorts were 71.00 [58.00, 81.00] years and 70.00 [59.00, 80.00] years, respectively. The proportions of chronic pulmonary disease patients in the training and validation cohorts were 13.2% and 13.1%, respectively. In the training and validation cohorts, 19.9% and 23.2% of patients had complicated

diabetes, respectively, while 39.0% and 36.7% of patients had another neurological insufficiency, respectively. The median SAPSII scores in the training and validation cohorts were 34.00 [27.00, 42.00] and 35.00 [28.00, 44.00], respectively. In the training and validation cohorts, the average blood glucose levels (mg/dL) were 137.00 [118.50, 164.12] and 143.00 [123.38, 166.75], respectively, while the average WBC counts (K/ μ L) were 10.70 [8.51, 13.57] and 10.80 [8.71, 13.50], respectively. The other baseline information is shown in Table 1.

Nomogram construction

Least absolute shrinkage and selection operator regression was applied to identify independent risk factors for mortality of ICH patients within 30 days. The different mean-squared errors within the range of log(lambda) were shown in Figure 2. When the cross-validation error was less than the standard error of the minimum value, the maximum lambda value was selected. Multivariate logistic regression identified age, GCS score, creatinine, WBC count, temperature, glucose, urine output, and bleeding volume as independent risk factors for mortality during hospitalization of ICH patients. The risk of mortality within 30 days was 1.05-fold higher for elderly patients (95% CI = 1.03-1.06). Patients with elevated WBCs at the first laboratory examination had a 1.1-fold higher risk of mortality than patients with normal results (95% CI = 1.05-1.16), while patients with a higher creatinine level had a 1.3-fold higher risk of mortality (95% CI = 1.10-1.55). Patients with hyperthermia when they entered the ICU had a 1.73-fold higher risk of mortality than patients with normal body temperature (95% CI = 1.25–2.41). Urine output (OR = 1.00, 95% CI = 1.00–1.00) and bleeding volume (OR = 1.02, 95% CI = 1.01-1.04) were also risk factors for 30-day mortality of ICH patients, while the GCS score (OR = 0.91, 95% CI = 0.86-0.95) was a protective factor (Table 2). These results were used to construct a nomogram for estimating the 30-day mortality risk of ICH patients (Figure 3).

Nomogram validation

The discriminative ability of the nomogram was summarized by the ROC and Harrell's concordance index (C-index). The C-indexes of the training and validation cohorts were 0.782 (95% CI = 0.740-0.820) and 0.778 (95% CI = 0.720-0.840), respectively. The overall predictive performance was verified using ROC curves (Figure 4). The AUCs of the nomogram were 0.772 (95% CI = 0.732-0.811) and 0.778 (95% CI = 0.719-0.838) in the training and validation cohorts, respectively. Our nomogram model had higher AUC values than SAPSII and OASIS in both the training and validation cohorts. In the training cohort, the optimal cut-off value of the nomogram was 0.276, and the sensitivity and specificity

were 0.789 and 0.637, respectively. In the validation cohort, the optimal cut-off value of the nomogram was 0.403, and the sensitivity and specificity were 0.697 and 0.780, respectively. The AUCs of the individual models were further compared using Delong's test. In the training cohort, the AUC of the nomogram did not significantly differ from those of SAPSII (P = 0.068) and OASIS (P = 0.384). In the validation cohort, our model exhibited a similar performance as SAPSII (P = 0.214, Delong's test) and OASIS (P = 0.158, Delong's test).

Compared with the traditional SAPSII and OASIS scoring systems, the NRI values of the nomogram were 0.257 (95% CI = -0.011-0.600) and 0.106 (95% CI = -0.082-0.405) in the training cohort, respectively, and 0.186 (95% CI = -0.192-0.670) and 0.178 (95% CI = -0.092-0.628) in the validation cohort, respectively. The corresponding IDI values were 0.048 (95% CI = 0.012-0.084), 0.028 (95% CI = -0.007-0.063), and 0.057 (95% CI = 0.001-0.112), 0.070 (95% CI = 0.018-0.123). These values indicate that our nomogram has a good discrimination ability comparable with these currently widely used scoring systems.

The calibration curve of the nomogram is shown in **Figure 5**. The calibration curves of the training and validation cohorts were both close to the diagonal. The Hosmer-Lemeshow test found no significant difference (training cohort: $\chi^2 = 11.043$, P = 0.199, validation cohort: $\chi^2 = 8.643$, P = 0.373). In summary, our nomogram provided a good simulation of the data. Finally, we drew a DCA curve to prove the clinical applicability of the nomogram and compared it with those of the SAPSII and OASIS scoring systems (**Figure 6**). When the threshold probability was 0.3–0.5, clinical intervention guided by our nomogram model had greater net benefit than that guided by the SAPSII and OASIS scoring systems in both cohorts.

Discussion

In this study, we identified independent risk factors for 30day mortality of ICH patients using LASSO and multivariate logistic regression. LASSO regression is one of the most useful tools to select features for classification and survival prognosis determination (Song et al., 2020). It can obtain fewer and more representative variable combinations from a large number of variables while avoiding model overfitting (Giral et al., 2018; Patel et al., 2018). However, LASSO regression also has shortcomings. It requires consistent initial estimates of regression coefficients, which are often unavailable in highdimensional settings (Alhamzawi and Ali, 2018). Furthermore, the result heavily depends on the penalty parameter λ , which can lead to a very high minimization of the false discovery rate in some cases (Ternès et al., 2016).

Our results showed that age, GCS score, creatinine, WBC count, temperature, glucose, urine output, and bleeding volume

TABLE 1 Patient characteristic.

Variables	Overall	Training cohort	Validation cohort	Р
N	890	623	267	
Gender (%)				
Female	402 (45.2)	292 (46.9)	110 (41.2)	0.138
Male	488 (54.8)	331 (53.1)	157 (58.8)	
Marital (%)				
DSW	194 (21.8)	133 (21.3)	61 (22.8)	0.885
Married	455 (51.1)	319 (51.2)	136 (50.9)	
Single	155 (17.4)	112 (18.0)	43 (16.1)	
Unknown	86 (9.7)	59 (9.5)	27 (10.1)	
Race (%)				
Black	63 (7.1)	39 (6.3)	24 (9.0)	0.329
Other	198 (22.2)	138 (22.2)	60 (22.5)	
White	629 (70.7)	446 (71.6)	183 (68.5)	
Age (year)	71.00 [58.00, 81.00]	71.00 [58.00, 81.00]	70.00 [59.00, 80.00]	0.959
Severe Score				
Angus	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.075
SAPSII	34.00 [27.25, 43.00]	34.00 [27.00, 42.00]	35.00 [28.00, 44.00]	0.26
SOFA	3.00 [2.00, 4.00]	3.00 [2.00, 4.00]	3.00 [2.00, 5.00]	0.252
OASIS	35.00 [29.00, 41.00]	35.00 [29.00, 41.00]	34.00 [29.00, 40.50]	0.872
APSIII	36.00 [26.25, 49.00]	36.00 [27.00, 50.00]	36.00 [26.00, 48.00]	0.570
GCS	14.00 [10.00, 15.00]	14.00 [10.00, 15.00]	14.00 [10.00, 15.00]	0.490
Laboratory test				
Anion gap (mmol/L)	14.50 [13.00, 16.19]	14.50 [13.00, 16.33]	14.00 [13.00, 16.00]	0.168
Bicarbonate (mmol/L)	24.50 [23.00, 26.63]	24.50 [23.00, 26.50]	25.00 [22.83, 26.67]	0.959
Creatinine (mg/dL)	0.90 [0.72, 1.15]	0.90 [0.70, 1.15]	0.90 [0.74, 1.16]	0.23
Chloride (mmol/L)	104.00 [101.00, 106.50]	104.00 [101.00, 106.50]	104.25 [101.59, 107.00]	0.050
Glucose (mg/dL)	138.38 [120.12, 164.73]	137.00 [118.50, 164.12]	143.00 [123.38, 166.75]	0.15
Hematocrit (g/dL)	36.53 [32.75, 39.83]	36.73 [33.11, 39.93]	35.80 [32.30, 39.50]	0.092
Hemoglobin (g/dL)	12.46 [11.20, 13.62]	12.53 [11.30, 13.60]	12.15 [10.98, 13.65]	0.129
Platelet (K/µL)	221.75 [176.62, 278.12]	224.00 [176.50, 279.75]	219.50 [177.29, 271.50]	0.374
Potassium (mmol/L)	3.89 [3.60, 4.20]	3.90 [3.61, 4.20]	3.86 [3.60, 4.15]	0.18
PTT (s)	26.40 [24.00, 29.30]	26.45 [24.10, 29.00]	26.15 [23.65, 30.03]	0.763
INR	1.13 [1.05, 1.30]	1.10 [1.05, 1.30]	1.15 [1.09, 1.35]	0.280
PT (s)	13.10 [12.50, 14.30]	13.05 [12.50, 14.20]	13.20 [12.45, 14.46]	0.429
Sodium (mmol/L)	139.67 [137.67, 141.75]	139.50 [137.50, 141.75]	140.00 [138.00, 141.71]	0.153
BUN (mmol/L)	17.00 [13.00, 22.92]	17.00 [13.33, 22.67]	17.33 [12.83, 23.00]	0.86
WBC (K/μL)	10.75 [8.55, 13.55]	10.70 [8.51, 13.57]	10.80 [8.71, 13.50]	0.78
Vital signs				017 0
Heartrate (bpm)	78.86 [69.96, 89.00]	79.31 [70.02, 88.62]	77.48 [69.39, 89.54]	0.398
Systolic BP (mmHg)	134.81 [124.40, 144.22]	134.96 [124.44, 144.85]	134.46 [124.01, 143.75]	0.400
Diastolic BP (mmHg)	64.51 [57.65, 71.84]	64.36 [57.69, 71.84]	65.26 [57.59, 71.76]	0.862
Mean BP (mmHg)	85.59 [78.09, 91.91]	85.68 [77.97, 92.43]	85.08 [78.41, 91.47]	0.80
Respiratory rate (rpm)	17.72 [15.91, 19.79]	17.73 [15.86, 19.86]	17.68 [15.95, 19.71]	0.97
Temperature (°C)	36.99 [36.57, 37.43]	37.02 [36.59, 37.41]	36.96 [36.54, 37.46]	0.593
SpO ₂ (%)	98.20 [96.77, 99.25]	98.04 [96.61, 99.26]	98.37 [97.05, 99.24]	0.179
Glucose (mg/dL)	139.17 [121.06, 162.76]	138.00 [120.80, 163.40]	140.60 [123.00, 161.12]	0.175
Urine Output (mL)	1742.50 [1176.25, 2540.00]	1740.00 [1150.00, 2550.00]	1748.00 [1226.00, 2477.50]	0.880

(Continued)

TABLE 1 (Continued)

Variables	Overall	Training cohort	Validation cohort	Р
Comorbidities				
Chronic pulmonary diseases (%)				
No	773 (86.9)	541 (86.8)	232 (86.9)	1.000
Yes	117 (13.1)	82 (13.2)	35 (13.1)	
Hypothyroidism (%)				
No	820 (92.1)	575 (92.3)	245 (91.8)	0.892
Yes	70 (7.9)	48 (7.7)	22 (8.2)	
Renal failure (%)				
No	826 (92.8)	577 (92.6)	249 (93.3)	0.843
Yes	64 (7.2)	46 (7.4)	18 (6.7)	
Liver Diseases (%)				
No	864 (97.1)	605 (97.1)	259 (97.0)	1.000
Yes	26 (2.9)	18 (2.9)	8 (3.0)	
Coagulopathy (%)				
No	828 (93.0)	584 (93.7)	244 (91.4)	0.262
Yes	62 (7.0)	39 (6.3)	23 (8.6)	
Obesity (%)				
No	872 (98.0)	611 (98.1)	261 (97.8)	0.959
Yes	18 (2.0)	12 (1.9)	6 (2.2)	
Fluid-electrolyte disorders (%)				
No	666 (74.8)	479 (76.9)	187 (70.0)	0.038
Yes	224 (25.2)	144 (23.1)	80 (30.0)	
Heart Diseases (%)				
No	513 (57.6)	361 (57.9)	152 (56.9)	0.836
Yes	377 (42.4)	262 (42.1)	115 (43.1)	
Diabetes (%)				
No	704 (79.1)	499 (80.1)	205 (76.8)	0.305
Yes	186 (20.9)	124 (19.9)	62 (23.2)	
Other neuronal dysfunctions (%)				
No	549 (61.7)	380 (61.0)	169 (63.3)	0.567
Yes	341 (38.3)	243 (39.0)	98 (36.7)	
Anemias (%)				
No	877 (98.5)	615 (98.7)	262 (98.1)	0.715
Yes	13 (1.5)	8 (1.3)	5 (1.9)	
Bleeding Volume (cm ²)	10.92 [5.94, 21.74]	11.88 [6.00, 22.20]	10.08 [5.25, 19.97]	0.075
Lesion Location (%)				
Basal ganglia	164 (18.4)	112 (18.0)	52 (19.5)	0.104
Brain stem	5 (0.6)	3 (0.5)	2 (0.7)	
Cerebel	91 (10.2)	65 (10.4)	26 (9.7)	
Frontal	175 (19.7)	129 (20.7)	46 (17.2)	
Intraparenchymal	121 (13.6)	81 (13.0)	40 (15.0)	
Occipital	36 (4.0)	22 (3.5)	14 (5.2)	
Parietal	51 (5.7)	32 (5.1)	19 (7.1)	
Subarachnoid	23 (2.6)	15 (2.4)	8 (3.0)	
Temporal	26 (2.9)	25 (4.0)	1 (0.4)	
Thalamic	36 (4.0)	29 (4.7)	7 (2.6)	
Unknown	162 (18.2)	110 (17.7)	52 (19.5)	

(Continued)

TABLE1 (Continued)

Overall	Training cohort	Validation cohort	Р
2.93 [1.84, 6.83]	2.93 [1.78, 6.34]	2.89 [1.88, 7.71]	0.303
8.25 [4.42, 14.65]	8.12 [4.28, 14.44]	8.60 [4.60, 15.76]	0.510
592 (66.5)	424 (68.1)	168 (62.9)	0.158
298 (33.5)	199 (31.9)	99 (37.1)	
	2.93 [1.84, 6.83] 8.25 [4.42, 14.65] 592 (66.5)	2.93 [1.84, 6.83] 2.93 [1.78, 6.34] 8.25 [4.42, 14.65] 8.12 [4.28, 14.44] 592 (66.5) 424 (68.1)	2.93 [1.84, 6.83] 2.93 [1.78, 6.34] 2.89 [1.88, 7.71] 8.25 [4.42, 14.65] 8.12 [4.28, 14.44] 8.60 [4.60, 15.76] 592 (66.5) 424 (68.1) 168 (62.9)



Least absolute shrinkage and selection operator (LASSO) binary logistic regression model for identifying independent risk factors for mortality in patients with ICH within 30 days. (A) LASSO coefficient profiles of the radiomic features. Each colored line represents the coefficient of each feature. (B) Plot the results of cross-validation, and the red dots in the figure represent the target parameters corresponding to each lambda. The largest lambda value is chosen when the cross-validation error is within one standard error of the minimum.

TABLE 2 Factors independently associated with 30-day mortality in ICH patients.

Variables	OR	95% CI	Р	
Age (year)	1.05	1.03-1.06	0.000	***
Severe Score				
GCS	0.91	0.86-0.95	0.000	***
Laboratory test				
Creatinine (mg/dL)	1.30	1.10-1.55	0.000	***
WBC (K/µL)	1.10	1.05-1.16	0.000	***
Vital signs				
Temperature (°C)	1.73	1.25-2.41	0.000	***
Glucose (mg/dL)	1.01	1.00 - 1.01	0.000	***
Urine Output (mL)	1.00	1.00 - 1.00	0.020	*
Bleeding Volume (cm ²)	1.02	1.01-1.04	0.000	***

*P < 0.05, ***P < 0.001.

were independent risk factors for 30-day mortality of ICH patients. These results were applied to construct a nomogram

model for assessing the 30-day mortality risk of ICH patients. The effectiveness of the nomogram was verified by multiple indicators, including the AUC, the calibration curve, the Hosmer-Lemeshow test, IDI, NRI, and DCA. In addition, we determined the best cut-off value according to the Youden index and calculated the sensitivity and specificity. In clinical applications, the selection of a cut-off value can be based on a trade-off between misdiagnosis and missed diagnosis. Although our model had higher AUC values than the SAPSII and OASIS scoring systems, further analysis using Delong's test did not reveal a significant difference (P > 0.05). However, several other indicators revealed that the predictive performance of the constructed nomogram was better than that of the SAPSII and OASIS scoring systems. These data indicate that the constructed model can reduce the number of variables and its predictive performance is not worse than that of commonly used scoring systems.

Similar to many previous studies, we found that age (Inoue et al., 2018; He et al., 2020), GCS score (Cui et al., 2020), and bleeding volume (Al-Shahi Salman et al., 2018; Du et al., 2020;



FIGURE 3

Thirty-day mortality nomogram for intracerebral hemorrhage. Nomogram included age, GCS, creatinine, WBC, temperature, glucose, urine output, and bleeding volume for predicting 30-day mortality after an acute intracerebral hemorrhage. The total point was calculated as the sum of the individual score of each of the seven variables included in the nomogram. The patient was evaluated according to each variable, and the total points were given according to the nomogram. The patient was evaluated according to the seven variable, and a total score was given according to the nomogram. Based on this value, the risk of 30-day morality could be predicted.

He et al., 2020; Kang et al., 2021; Masotti et al., 2021; Pasi et al., 2021) were independent risk factors for the poor prognosis of ICH patients. It is generally believed that the main causes of ICH are hypertension and CAA (Schrag and Kirshner, 2020). CAA is believed to be directly related to aging (Dallaire-Théroux et al., 2022). It has also been suggested that the hematoma volume (Kuramatsu et al., 2011; Forti et al., 2016; Inoue et al., 2018) and neuroinflammation (Jiang et al., 2021; Watson et al., 2022) are more critical in elderly patients with ICH. The GCS score is the most widely used indicator for assessing the degree of coma in patients, and lower GCS scores are associated with a higher risk of death (Saika et al., 2015; Widyadharma et al., 2021). Consistent with our results, many nomogram-based studies have reported that a decrease in GCS scores significantly contributes to an increase in mortality and the likelihood of hematoma expansion in ICH patients (Yao et al., 2015; Cui et al., 2020; Chen et al., 2021; Kang et al., 2021). The bleeding volume increases upon rupture of vessels and can continue to increase after ICH is diagnosed by imaging,

and, consequently, the baseline bleeding volume and hematoma enlargement are strongly associated with poor clinical outcomes (Al-Shahi Salman et al., 2018). The bleeding volume has even been reported to be the main determinant of outcomes after ICH (LoPresti et al., 2014).

Although the pathology has not been fully elucidated, ICH is accompanied by a strong inflammatory cascade, including infiltration of leukocytes, release of various inflammatory factors, and activation of microglia (Tschoe et al., 2020). Peripheral blood leukocytes are a marker of the immune response and reflect activation of the inflammatory cascade after spontaneous ICH, which causes secondary brain damage (Tapia-Pérez et al., 2016; Zhang et al., 2019). Many studies have suggested that elevated leukocyte levels are associated with worsening neurological function and increased mortality of ICH patients, consistent with our results (Lattanzi et al., 2018; Yu et al., 2019).

An elevated temperature may be caused by the inflammatory response (Iglesias-Rey et al., 2018). Up to 30–40% of





ICH patients reportedly have hyperthermia and a poor prognosis (Honig et al., 2015; Liddle et al., 2022). However, in the absence of other infection signs, persistent high fever in ICH patients may be induced by perturbation of temperature control (Rabinstein and Sandhu, 2007). High fever may cause adverse events such as hematoma growth, blood-brain barrier destruction, edema, decreased cerebral blood flow, elevation of pro-inflammatory cytokines, and axon death (Balami and Buchan, 2012). Furthermore, antihyperthermia therapy is believed to positively affect the



FIGURE 6

Decision-curve analysis of the training cohort and the validation cohort. Decision curve analysis depicts the clinical net benefit in pairwise comparisons across the different models. The red line indicates the nomogram, which is the model we built. The green line indicates SAPSII scoring system and the blue line indicates OASIS. Nomogram showed superior net benefit with a wider range of threshold probabilities compared with SAPSII and OASIS.

prognosis of ICH patients (Fischer et al., 2017; Hervella et al., 2020).

In our nomogram model, ICH patients with abnormal blood glucose levels were at increased risk of an unfavorable prognosis, consistent with other studies (Saxena et al., 2016; Wada et al., 2018; Guo et al., 2019). Elevated blood glucose levels may lead to activation of the coagulation system, inhibition of the fibrinolytic system, and production of free radicals. In addition, they may also lead to acidosis, production of excitatory amino acids, and damage of the blood-brain barrier, thereby causing secondary ischemic brain damage (Wada et al., 2018). Similar to our results, nomogram models constructed by other scholars demonstrate that an elevated blood glucose level is a risk factor for the occurrence of ICH in patients receiving thrombolytic therapy and for the poor prognosis of ICH patients (Yeo et al., 2017; Zhou et al., 2020).

Nearly one-third of hospitalized ICH patients reportedly have chronic kidney disease, possibly due to a common pathogenic mechanism and causal relationship between ICH and chronic kidney disease (Ovbiagele et al., 2014; Meier et al., 2018; Marini et al., 2020). These patients also had slightly poorer quality of care and significantly higher mortality than patients with normal renal function (Ovbiagele et al., 2014). Although the underlying mechanism remains unclear, numerous studies have found that indicators of renal insufficiency, including elevated serum creatinine levels, are independent predictors of in-hospital mortality and hematoma expansion in ICH patients (Wang and Zhang, 2017; Zhang et al., 2021).

The severity of acute kidney injury is associated with an increased serum creatinine level and decreased urine output (Kellum et al., 2015). However, we found that increased urine output was an independent risk factor for death of ICH patients. This topic has barely been previously studied. Polyuria is a very common lower urinary tract symptom in patients with neurological diseases and may involve central injury, lower urinary tract, kidney, and cardiovascular dysfunctions, and diabetes (Haddad et al., 2020). Hypothermia treatment in patients with severe traumatic brain injury may avoid the need for additional brain injury treatments that may lead to increased urine output and subsequent severe electrolyte depletion (e.g., hypophosphatemia and hypomagnesemia) (Polderman et al., 2001). In addition, increased urine output may be related to arginine vasopressin and copeptin (Christ-Crain, 2019). Plasma copeptin concentrations are reportedly significantly increased after ICH (Senn et al., 2014; Aksu et al., 2016). The increase in copeptin is correlated with the hematoma volume (Dong et al., 2011). Copeptin is directly associated with the clinical severity of ICH and poor prognostic outcomes after ICH. This may explain why ICH patients with polyuria have increased mortality (Zweifel et al., 2010; Zhang et al., 2012; Wei et al., 2014).

Although not addressed in this study, we believe that attention should be paid to parameters associated with mechanical ventilation weaning in ICH patients. Patients with severe ICH are at risk of dyspnea that requires endotracheal intubation and mechanical ventilation (Gujjar et al., 1998). However, delayed weaning may lead to increased mortality rates, complication rates, and lengths of hospital stay (Coplin et al., 2000). Traditional weaning parameters, such as the rapid shallow breathing index and negative inspiratory force, are often used as clinical indicators of mechanical ventilation (Savla et al., 2021). However, they are not always reliable in patients with brain injuries, including those who cannot achieve maximal spontaneous inspiration (dos Reis et al., 2013). Therefore, it is necessary to include indicators of optimal mechanical ventilation weaning in predictive models by logistic regression. However, in the current study, more than 20% of mechanical ventilation data were missing and this indicator was eliminated prior to analysis.

A clinical prediction model is an intuitive tool used to study the relationship between a patient's prognosis with a specific disease and the baseline status. It helps clinicians more accurately and systematically predict the probability of a patient outcome event occurring. ICH is a stroke syndrome with a very unfavorable prognosis that widely affects the health of the public. Therefore, it is very important to build a model that can predict the mortality of ICH patients. A nomogram is a commonly used tool to evaluate oncology and medical prognosis and can graphically represent complex mathematical formulas (Balachandran et al., 2015). We reviewed several studies of nomogram prediction models with ICH patient outcomes as endpoints and found they included data on adult ICH patients (patient numbers ranging from 200 to 1000) at one or several medical centers (Cui et al., 2020; Du et al., 2020; He et al., 2020; Kang et al., 2021). All studies excluded patients with secondary ICH. Two of these studies defined the location of bleeding (Cui et al., 2020; Kang et al., 2021) and Du et al. constructed their nomogram prediction model using only imaging data (Du et al., 2020). By contrast, we did not define the location of bleeding and included it in the parameters to determine whether the bleeding at different locations affects the prognosis of patients. Furthermore, increased urine output was associated with the death of ICH patients in our model.

An advantage of our study is that the vast amount of clinical data in a public database was exploited using data mining technology. Data mining is a new field in medical research. It can build disease prediction models to assess patient risk and assist clinical decision-making by making full use of big data in public databases such as MIMIC-III and Surveillance, Epidemiology, and End Results (Yang et al., 2020; Wu et al., 2021). Numerous studies have confirmed the availability and authenticity of data in the MIMIC-III database. At the same time, possible biases in patient selection were excluded to a certain extent. In addition, the use of a large amount of data avoided errors associated with the use of fewer data, providing reliable evidence for our results.

However, our study has some limitations. Although a large number of patients were included, it was a single-center study. In addition, the included cases were mostly

white therefore there may be some potential bias, and further external validation is needed to eliminate errors. In this study, we used LASSO and logistic regression in machine learning to identify variables and build a nomogram model, and did not employ other machine learning methods, such as Elastic Network Regression, Support Vector Machine, and Artificial Neural Networks. Furthermore, after screening, our model found no unexpected independent risk factors other than increased urine output. Moreover, multivariate logistic regression found that the ORs of each independent risk factor were close to 1. Further external validation using data of a subset of patients from this medical center is required to improve the confidence of the results. Nevertheless, we believe that the proposed model may contribute to further understanding of the mortality of ICH patients.

Conclusion

The study identified independent risk factors for 30-day mortality in ICH patients and used them to construct a predictive nomogram model. The results of our study may provide support for improving the prognosis of ICH patients.

Relevance for clinical practice

We developed a nomogram model to predict the 30-day mortality in patients with ICH based on baseline characteristics, laboratory tests, and imaging data of ICH patients admitted to the ICU from the MIMIC-III database. Compared with the SAPSII and OASIS systems, the nomogram has comparable performance in predicting mortality of patients with ICH. It's more concise and easier to use, thus providing a new reference guideline for the treatment and care of patients with ICH.

Data availability statement

The original contributions presented in this study are included in the **Supplementary data sheet 1**, further inquiries can be directed to the corresponding authors. The original data are available on the MIMIC-III website at https://mimic. physionet.org/, http://dx.doi.org/10.13026/C2XW26.

Ethics statement

The study was an analysis of a third-party anonymized publicly available database with pre-existing institutional review board (IRB) approval. Data extracted from the MIMIC III database do not require individual informed consent because MIMIC III database research data is publicly available, and all patient data are de-identified.

Author contributions

MT conceived the study. JZ created the study protocol, performed the statistical analyses, and wrote the first manuscript draft. HC conceived the study and critically revised the manuscript. CL assisted with the study design and performed the data collection. ZC, JY, YZ, and SL assisted with study coordination and helped draft the manuscript. HL assisted with manuscript revision and data confirmation. MT contributed to data interpretation and manuscript revision. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (nos. 32071033, 81771331, and 32170977).

Acknowledgments

We specially thank Professor Jun Lyu for statistical support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fnins.2022.942100/full#supplementary-material

SUPPLEMENTARY DATA 1 Raw data.

SUPPLEMENTARY DATA 2 Code for LASSO analysis.

References

Aksu, F., Gurger, M., Yilmaz, M., Atescelik, M., Yildiz, M., Ilhan, N., et al. (2016). Copeptin levels in cerebral infarction, intracranial hemorrhage and subarachnoid hemorrhage. *Clin. Lab.* 62, 2387–2393. doi: 10.7754/Clin.Lab.2016. 160532

Alhamzawi, R., and Ali, H. T. M. (2018). The Bayesian adaptive lasso regression. Math. Biosci. 303, 75–82. doi: 10.1016/j.mbs.2018.06.004

Al-Shahi Salman, R., Frantzias, J., Lee, R. J., Lyden, P. D., Battey, T. W. K., Ayres, A. M., et al. (2018). Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: A systematic review and meta-analysis of individual patient data. *Lancet Neurol.* 17, 885–894. doi: 10.1016/s1474-4422(18) 30253-9

An, S. J., Kim, T. J., and Yoon, B. W. (2017). Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: An update. *J. Stroke* 19, 3–10. doi: 10.5853/jos.2016.00864

Balachandran, V. P., Gonen, M., Smith, J. J., and DeMatteo, R. P. (2015). Nomograms in oncology: More than meets the eye. *Lancet Oncol.* 16, e173-80. doi: 10.1016/s1470-2045(14)71116-7

Balami, J. S., and Buchan, A. M. (2012). Complications of intracerebral haemorrhage. *Lancet Neurol*. 11, 101–118. doi: 10.1016/s1474-4422(11)70264-2

Banerjee, G., Carare, R., Cordonnier, C., Greenberg, S. M., Schneider, J. A., Smith, E. E., et al. (2017). The increasing impact of cerebral amyloid angiopathy: Essential new insights for clinical practice. *J. Neurol. Neurosurg. Psychiatry* 88, 982–994. doi: 10.1136/jnnp-2016-314697

Cai, Q., Zhang, X., and Chen, H. (2021). Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: A review. *Thromb. J.* 19:93. doi: 10.1186/s12959-021-00345-z

Chen, Q., Zhu, D., Liu, J., Zhang, M., Xu, H., Xiang, Y., et al. (2021). Clinicalradiomics nomogram for risk estimation of early hematoma expansion after acute intracerebral hemorrhage. Acad. Radiol. 28, 307-317. doi: 10.1016/j.acra.2020.02. 021

Christ-Crain, M. (2019). Vasopressin and Copeptin in health and disease. Rev. Endocr. Metab. Disord. 20, 283–294. doi: 10.1007/s11154-019-09509-9

Coplin, W. M., Pierson, D. J., Cooley, K. D., Newell, D. W., and Rubenfeld, G. D. (2000). Implications of extubation delay in brain-injured patients meeting standard weaning criteria. *Am. J. Respir. Crit. Care Med.* 161, 1530–1536. doi: 10.1164/ajrccm.161.5.9905102

Cui, Z., Liu, C., Sun, G., Huang, L., and Zhou, W. (2020). A prognostic nomogram incorporating red cell distribution width for patients with intracerebral hemorrhage. *Medicine* 99:e23557. doi: 10.1097/md.000000000023557

Dallaire-Théroux, C., Saikali, S., Richer, M., Potvin, O., and Duchesne, S. (2022). Histopathological analysis of cerebrovascular lesions associated with aging. *J. Neuropathol. Exp. Neurol.* 81, 97–105. doi: 10.1093/jnen/nlab125

DeLong, E. R., DeLong, D. M., and Clarke-Pearson, D. L. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. *Biometrics* 44, 837–845.

Devan, W. J., Falcone, G. J., Anderson, C. D., Jagiella, J. M., Schmidt, H., Hansen, B. M., et al. (2013). Heritability estimates identify a substantial genetic contribution to risk and outcome of intracerebral hemorrhage. *Stroke* 44, 1578– 1583. doi: 10.1161/strokeaha.111.000089

Dong, X. Q., Huang, M., Yu, W. H., Zhang, Z. Y., Zhu, Q., Che, Z. H., et al. (2011). Change in plasma copeptin level after acute spontaneous basal ganglia hemorrhage. *Peptides* 32, 253–257. doi: 10.1016/j.peptides.2010.11.021

dos Reis, H. F., Almeida, M. L., da Silva, M. F., Moreira, J. O., and Rocha Mde, S. (2013). Association between the rapid shallow breathing index and extubation success in patients with traumatic brain injury. *Rev. Bras. Ter. Intensiva* 25, 212–217. doi: 10.5935/0103-507x.20130037

Du, C., Liu, B., Yang, M., Zhang, Q., Ma, Q., and Ruili, R. (2020). Prediction of poor outcome in intracerebral hemorrhage based on computed tomography markers. *Cerebrovasc. Dis.* 49, 556–562. doi: 10.1159/000510805

Fischer, M., Schiefecker, A., Lackner, P., Frank, F., Helbok, R., Beer, R., et al. (2017). Targeted temperature management in spontaneous intracerebral hemorrhage: A systematic review. *Curr. Drug Targets* 18, 1430–1440. doi: 10.2174/1389450117666160703161511

Forti, P., Maioli, F., Domenico Spampinato, M., Barbara, C., Nativio, V., Coveri, M., et al. (2016). The effect of age on characteristics and mortality of intracerebral hemorrhage in the oldest-old. *Cerebrovasc. Dis.* 42, 485–492. doi: 10.1159/000448813

Giral, M., Renaudin, K., Naesens, M., Luning, R., Anglicheau, D., Morelon, E., et al. (2018). The 1-year renal biopsy index: A scoring system to drive biopsy indication at 1-year post-kidney transplantation. *Transpl Int.* Online ahead of print, doi: 10.1111/tri.13290

Gon, Y., Todo, K., Mochizuki, H., and Sakaguchi, M. (2018). Cancer is an independent predictor of poor outcomes in patients following intracerebral hemorrhage. *Eur. J. Neurol.* 25, 128–134. doi: 10.1111/ene.13456

Gujjar, A. R., Deibert, E., Manno, E. M., Duff, S., and Diringer, M. N. (1998). Mechanical ventilation for ischemic stroke and intracerebral hemorrhage: Indications, timing, and outcome. *Neurology* 51, 447–451. doi: 10.1212/wnl.51.2. 447

Guo, R., Chen, R., You, C., Ma, L., Li, H., and Fang, Y. (2019). Glucose levels and outcome after primary intraventricular hemorrhage. *Curr. Neurovasc. Res.* 16, 40–46. doi: 10.2174/1567202616666190131164108

Haddad, R., Denys, P., Arlandis, S., Giannantoni, A., Del Popolo, G., Panicker, J. N., et al. (2020). Nocturia and nocturnal polyuria in neurological patients: From epidemiology to treatment. A systematic review of the literature. *Eur. Urol. Focus* 6, 922–934. doi: 10.1016/j.euf.2020.02.007

He, X. W., Chen, M. D., Du, C. N., Zhao, K., Yang, M. F., and Ma, Q. F. (2020). A novel model for predicting the outcome of intracerebral hemorrhage: Based on 1186 Patients. *J. Stroke Cerebrovasc. Dis.* 29:104867. doi: 10.1016/j. jstrokecerebrovasdis.2020.104867

Hemphill, J. C. III, Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., et al. (2015). Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 46, 2032–2060. doi: 10.1161/str.000000000000069

Hervella, P., Rodríguez-Yáñez, M., Pumar, J. M., Ávila-Gómez, P., da Silva-Candal, A., López-Loureiro, I., et al. (2020). Antihyperthermic treatment decreases perihematomal hypodensity. *Neurology* 94, e1738–e1748. doi: 10.1212/wnl. 00000000009288

Honig, A., Michael, S., Eliahou, R., and Leker, R. R. (2015). Central fever in patients with spontaneous intracerebral hemorrhage: Predicting factors and impact on outcome. *BMC Neurol* 15:6. doi: 10.1186/s12883-015-0258-8

Hostettler, I. C., Seiffge, D. J., and Werring, D. J. (2019). Intracerebral hemorrhage: An update on diagnosis and treatment. *Expert Rev. Neurother.* 19, 679–694. doi: 10.1080/14737175.2019.1623671

Iglesias-Rey, R., Rodríguez-Yáñez, M., Arias, S., Santamaría, M., Rodríguez-Castro, E., López-Dequidt, I., et al. (2018). Inflammation, edema and poor outcome are associated with hyperthermia in hypertensive intracerebral hemorrhages. *Eur. J. Neurol.* 25, 1161–1168. doi: 10.1111/ene.13677

Inoue, Y., Miyashita, F., Minematsu, K., and Toyoda, K. (2018). Clinical characteristics and outcomes of intracerebral hemorrhage in very elderly. *J. Stroke Cerebrovasc. Dis.* 27, 97–102. doi: 10.1016/j.jstrokecerebrovasdis.2017.08.006

Jiang, B., Zhang, Y., Wang, Y., Li, Z., Chen, Q., Tang, J., et al. (2021). Glibenclamide attenuates neuroinflammation and promotes neurological recovery after intracerebral hemorrhage in aged rats. *Front. Aging Neurosci.* 13:729652. doi: 10.3389/fnagi.2021.729652

Johnson, A. E., Pollard, T. J., Shen, L., Lehman, L. W., Feng, M., Ghassemi, M., et al. (2016). MIMIC-III, a freely accessible critical care database. *Sci. Data* 3:160035. doi: 10.1038/sdata.2016.35

Jones, F. E., Murray, L. S., McNeilly, S., Dean, A., Aman, A., Lu, Y., et al. (2019). 4-Sodium phenyl butyric acid has both efficacy and counter-indicative effects in the treatment of Col4a1 disease. *Hum. Mol. Genet.* 28, 628–638. doi: 10.1093/hmg/ddy369

Kang, H., Cai, Q., Gong, L., and Wang, Y. (2021). Nomogram prediction of short-term outcome after intracerebral hemorrhage. *Int. J. Gen. Med.* 14, 5333–5343. doi: 10.2147/ijgm.S330742

Kellum, J. A., Sileanu, F. E., Murugan, R., Lucko, N., Shaw, A. D., and Clermont, G. (2015). Classifying AKI by urine output versus serum creatinine level. J. Am. Soc. Nephrol. 26, 2231–2238. doi: 10.1681/asn.2014070724

Kirshner, H., and Schrag, M. (2021). Management of intracerebral hemorrhage: Update and future therapies. *Curr. Neurol. Neurosci. Rep.* 21:57. doi: 10.1007/ s11910-021-01144-9

Kuramatsu, J. B., Sauer, R., Mauer, C., Lücking, H., Kloska, S. P., Kiphuth, I. C., et al. (2011). Correlation of age and haematoma volume in patients with spontaneous lobar intracerebral haemorrhage. *J. Neurol. Neurosurg. Psychiatry* 82, 144–149. doi: 10.1136/jnnp.2010.208439

Lattanzi, S., Cagnetti, C., Rinaldi, C., Angelocola, S., Provinciali, L., and Silvestrini, M. (2018). Neutrophil-to-lymphocyte ratio improves outcome prediction of acute intracerebral hemorrhage. *J. Neurol. Sci.* 387, 98–102. doi: 10.1016/j.jns.2018.01.038

Liddle, L. J., Dirks, C. A., Almekhlafi, M., and Colbourne, F. (2022). An ambiguous role for fever in worsening outcome after intracerebral hemorrhage. *Transl. Stroke Res.* Online ahead of print, doi: 10.1007/s12975-022-01010-x

LoPresti, M. A., Bruce, S. S., Camacho, E., Kunchala, S., Dubois, B. G., Bruce, E., et al. (2014). Hematoma volume as the major determinant of outcomes after intracerebral hemorrhage. *J. Neurol. Sci.* 345, 3–7. doi: 10.1016/j.jns.2014.06.057

Lord, A. S., Langefeld, C. D., Sekar, P., Moomaw, C. J., Badjatia, N., Vashkevich, A., et al. (2014). Infection after intracerebral hemorrhage: Risk factors and association with outcomes in the ethnic/racial variations of intracerebral hemorrhage study. *Stroke* 45, 3535–3542. doi: 10.1161/strokeaha.114.006435

Marini, S., Georgakis, M. K., Chung, J., Henry, J. Q. A., Dichgans, M., Rosand, J., et al. (2020). Genetic overlap and causal inferences between kidney function and cerebrovascular disease. *Neurology* 94, e2581–e2591. doi: 10.1212/ wnl.000000000009642

Masotti, L., Grifoni, E., Migli, L., Dei, A., Spina, R., Calamai, I., et al. (2021). Prognostic determinants in patients with non traumatic intracerebral hemorrhage: A real life report. *Acta Clin. Belg.* 76, 365–372. doi: 10.1080/17843286.2020. 1750151

Meier, K., Saenz, D. M., Torres, G. L., Cai, C., Rahbar, M. H., McDonald, M., et al. (2018). Thrombelastography suggests hypercoagulability in patients with renal dysfunction and intracerebral hemorrhage. *J. Stroke Cerebrovasc. Dis.* 27, 1350–1356. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.026

Morotti, A., and Goldstein, J. N. (2016). Diagnosis and management of acute intracerebral hemorrhage. *Emerg. Med. Clin. North Am.* 34, 883–899. doi: 10.1016/j.emc.2016.06.010

Ovbiagele, B., Schwamm, L. H., Smith, E. E., Grau-Sepulveda, M. V., Saver, J. L., Bhatt, D. L., et al. (2014). Hospitalized hemorrhagic stroke patients with renal insufficiency: Clinical characteristics, care patterns, and outcomes. *J. Stroke Cerebrovasc. Dis.* 23, 2265–2273. doi: 10.1016/j.jstrokecerebrovasdis.2014.04.016

Parry-Jones, A. R., Moullaali, T. J., and Ziai, W. C. (2020). Treatment of intracerebral hemorrhage: From specific interventions to bundles of care. *Int. J. Stroke* 15, 945–953. doi: 10.1177/1747493020964663

Pasi, M., Casolla, B., Kyheng, M., Boulouis, G., Kuchcinski, G., Moulin, S., et al. (2021). Long-term functional decline of spontaneous intracerebral haemorrhage survivors. *J. Neurol. Neurosurg. Psychiatry* 92, 249–254. doi: 10.1136/jnnp-2020-324741

Patel, S. J., Chamberlain, D. B., and Chamberlain, J. M. (2018). A machine learning approach to predicting need for hospitalization for pediatric asthma exacerbation at the time of emergency department triage. *Acad. Emerg. Med.* 25, 1463–1470. doi: 10.1111/acem.13655

Polderman, K. H., Peerdeman, S. M., and Girbes, A. R. (2001). Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury. *J. Neurosurg.* 94, 697–705. doi: 10.3171/jns.2001.94.5. 0697

Rabinstein, A. A., and Sandhu, K. (2007). Non-infectious fever in the neurological intensive care unit: Incidence, causes and predictors. J. Neurol. Neurosurg. Psychiatry 78, 1278–1280. doi: 10.1136/jnnp.2006.112730

Saika, A., Bansal, S., Philip, M., Devi, B. I., and Shukla, D. P. (2015). Prognostic value of FOUR and GCS scores in determining mortality in patients with traumatic brain injury. *Acta Neurochir*. 157, 1323–1328. doi: 10.1007/s00701-015-2469-6

Savla, P., Toor, H., Podkovik, S., Mak, J., Kal, S., Soliman, C., et al. (2021). A reassessment of weaning parameters in patients with spontaneous intracerebral hemorrhage. *Cureus* 13:e12539. doi: 10.7759/cureus.12539

Saxena, A., Anderson, C. S., Wang, X., Sato, S., Arima, H., Chan, E., et al. (2016). Prognostic significance of hyperglycemia in acute intracerebral hemorrhage: The INTERACT2 study. *Stroke* 47, 682–688. doi: 10.1161/strokeaha.115.01 1627

Schrag, M., and Kirshner, H. (2020). Management of intracerebral hemorrhage: JACC focus seminar. J. Am. Coll. Cardiol. 75, 1819–1831. doi: 10.1016/j.jacc.2019. 10.066

Schreiber, S., Wilisch-Neumann, A., Schreiber, F., Assmann, A., Scheumann, V., Perosa, V., et al. (2020). Invited review: The spectrum of age-related small vessel diseases: Potential overlap and interactions of amyloid and nonamyloid vasculopathies. *Neuropathol. Appl. Neurobiol.* 46, 219–239. doi: 10.1111/nan. 12576

Senn, R., Elkind, M. S., Montaner, J., Christ-Crain, M., and Katan, M. (2014). Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage. *Cerebrovasc. Dis.* 38, 395–409. doi: 10.1159/000366470

Song, J., Yin, Y., Wang, H., Chang, Z., Liu, Z., and Cui, L. (2020). A review of original articles published in the emerging field of radiomics. *Eur. J. Radiol.* 127:108991. doi: 10.1016/j.ejrad.2020.108991

Tang, L., Yang, Q., Liu, X., Tian, D., Wu, C., Han, Q., et al. (2021). Mutation analysis of the GLA gene in Chinese patients with intracerebral hemorrhage. *Neurobiol. Aging* 102, e1-220.e4. doi: 10.1016/j.neurobiolaging.2021.01.027

Tapia-Pérez, J. H., Karagianis, D., Zilke, R., Koufuglou, V., Bondar, I., and Schneider, T. (2016). Assessment of systemic cellular inflammatory response after spontaneous intracerebral hemorrhage. *Clin. Neurol. Neurosurg.* 150, 72–79. doi: 10.1016/j.clineuro.2016.07.010

Ternès, N., Rotolo, F., and Michiels, S. (2016). Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models. *Stat. Med.* 35, 2561–2573. doi: 10.1002/sim.6927

Tschoe, C., Bushnell, C. D., Duncan, P. W., Alexander-Miller, M. A., and Wolfe, S. Q. (2020). Neuroinflammation after intracerebral hemorrhage and potential therapeutic targets. *J. Stroke* 22, 29–46. doi: 10.5853/jos.2019.02236

Wada, S., Yoshimura, S., Inoue, M., Matsuki, T., Arihiro, S., Koga, M., et al. (2018). Outcome prediction in acute stroke patients by continuous glucose monitoring. *J. Am. Heart Assoc.* 7:e008744. doi: 10.1161/jaha.118.008744

Wang, G., and Zhang, J. (2017). Hematoma expansion: Clinical and molecular predictors and corresponding pharmacological treatment. *Curr Drug Targets* 18, 1367–1376. doi: 10.2174/1389450117666160712092224

Watson, N., Bonsack, F., and Sukumari-Ramesh, S. (2022). Intracerebral hemorrhage: The effects of aging on brain injury. *Front. Aging Neurosci.* 14:859067. doi: 10.3389/fnagi.2022.859067

Weber, S. A., Patel, R. K., and Lutsep, H. L. (2018). Cerebral amyloid angiopathy: Diagnosis and potential therapies. *Expert Rev. Neurother.* 18, 503–513. doi: 10. 1080/14737175.2018.1480938

Wei, Z. J., Ou, Y. Q., Li, X., and Li, H. (2014). The 90-day prognostic value of copeptin in acute intracerebral hemorrhage. *Neurol. Sci.* 35, 1673–1679. doi: 10.1007/s10072-014-1809-2

Widyadharma, I. P. E., Krishna, A., Soejitno, A., Laksmidewi, A., Tini, K., Putra, I. B. K., et al. (2021). Modified ICH score was superior to original ICH score for assessment of 30-day mortality and good outcome of non-traumatic intracerebral hemorrhage. *Clin. Neurol. Neurosurg.* 209:106913. doi: 10.1016/j.clineuro.2021. 106913

Wilkinson, D. A., Pandey, A. S., Thompson, B. G., Keep, R. F., Hua, Y., and Xi, G. (2018). Injury mechanisms in acute intracerebral hemorrhage. *Neuropharmacology* 134(Pt. B), 240–248. doi: 10.1016/j.neuropharm.2017.09.033 Wu, W. T., Li, Y. J., Feng, A. Z., Li, L., Huang, T., Xu, A. D., et al. (2021). Data mining in clinical big data: The frequently used databases, steps, and methodological models. *Mil. Med. Res.* 8:44. doi: 10.1186/s40779-021-00338-z

Xu, F., Zhang, L., Wang, Z., Han, D., Li, C., Zheng, S., et al. (2021). A new scoring system for predicting in-hospital death in patients having liver cirrhosis with esophageal varices. *Front. Med.* 8:678646. doi: 10.3389/fmed.2021.678646

Yang, J., Li, Y., Liu, Q., Li, L., Feng, A., Wang, T., et al. (2020). Brief introduction of medical database and data mining technology in big data era. *J. Evid. Based Med.* 13, 57–69. doi: 10.1111/jebm.12373

Yao, X., Xu, Y., Siwila-Sackman, E., Wu, B., and Selim, M. (2015). The HEP score: A nomogram-derived hematoma expansion prediction scale. *Neurocrit. Care* 23, 179–187. doi: 10.1007/s12028-015-0147-4

Yeo, L. L. L., Chien, S. C., Lin, J. R., Liow, C. W., Lee, J. D., Peng, T. I., et al. (2017). Derivation and validation of a scoring system for intravenous tissue plasminogen activator use in asian patients. *J. Stroke Cerebrovasc. Dis* 26, 1695–1703. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.033

Yu, Z., Zheng, J., Guo, R., Ma, L., You, C., and Li, H. (2019). Prognostic impact of leukocytosis in intracerebral hemorrhage: A PRISMA-compliant systematic review and meta-analysis. *Medicine* 98:e16281. doi: 10.1097/md.00000000001 6281

Zhang, C., Xia, J., Ge, H., Zhong, J., Chen, W., Lan, C., et al. (2021). Longterm mortality related to acute kidney injury following intracerebral hemorrhage: A 10-Year (2010-2019) retrospective study. *J. Stroke Cerebrovasc. Dis.* 30:105688. doi: 10.1016/j.jstrokecerebrovasdis.2021.105688

Zhang, F., Ren, Y., Fu, W., Yang, Z., Wen, D., Hu, X., et al. (2019). Predictive accuracy of neutrophil-to-lymphocyte ratio on long-term outcome in patients with spontaneous intracerebral hemorrhage. *World Neurosurg.* 125, e651–e657. doi: 10.1016/j.wneu.2019.01.143

Zhang, X., Lu, X. M., Huang, L. F., and Ye, H. (2012). Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage. *Peptides* 33, 336–341. doi: 10.1016/j.peptides.2012.01. 011

Zhang, Z., and Hong, Y. (2017). Development of a novel score for the prediction of hospital mortality in patients with severe sepsis: The use of electronic healthcare records with LASSO regression. *Oncotarget* 8, 49637–49645. doi: 10. 18632/oncotarget.17870

Zheng, Z., Zhang, Y., Zhang, L., Li, Z., Wu, X., Liu, Y., et al. (2016). A nomogram for predicting the likelihood of lymph node metastasis in early gastric patients. *BMC Cancer* 16:92. doi: 10.1186/s12885-016-2132-5

Zhou, Z., Yin, X., Niu, Q., Liang, S., Mu, C., and Zhang, Y. (2020). Risk factors and a nomogram for predicting intracranial hemorrhage in stroke patients undergoing thrombolysis. *Neuropsychiatr. Dis. Treat.* 16, 1189–1197. doi: 10.2147/ndt.S250648

Zweifel, C., Katan, M., Schuetz, P., Siegemund, M., Morgenthaler, N. G., Merlo, A., et al. (2010). Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. *BMC Neurol.* 10:34. doi: 10.1186/1471-2377-10-34